论文部分内容阅读
由于胰岛素抵抗及其相关的代偿性高胰岛素血症是引起胰岛β细胞功能不全进展的病因之一,故纠正或减轻胰岛素抵抗可减慢或防止胰岛素抵抗相关性糖尿病病人胰岛β细胞功能的进一步恶化。由于噻唑烷二酮类药物是减轻胰岛素抵抗的最有效的药物,可以预期这类药物治疗将减慢或防止胰岛β细胞功能的进一步恶化。因此,通过观察胰岛素强化治疗及其与口服噻唑烷二酮类药物联合治疗,了解其对初诊2型糖尿病患者近期血糖控制的影响。
Since insulin resistance and its associated compensatory hyperinsulinemia are one of the causes of the progression of pancreatic β-cell insufficiency, correcting or reducing insulin resistance may slow or prevent the function of pancreatic β-cells in patients with insulin resistance-related diabetes mellitus deterioration. Since thiazolidinediones are the most effective drugs to reduce insulin resistance, it is expected that such drug treatment will slow down or prevent further deterioration of pancreatic β-cell function. Therefore, by observing the intensive insulin therapy and oral thiazolidinediones and thiazolidinediones in combination therapy to understand the impact of its recent treatment of type 2 diabetes patients with recent blood sugar control.